ZOGENIX INTERNATIONAL LIMITED maintains an average payment time of 44 days, positioning most transactions within the 31-60 day bracket and indicating a consistent tendency to pay beyond standard 30-day terms. While 52% of payments are made within 30 days, the remaining 48% extend further, with 16% exceeding 60 days, suggesting a split payment behavior rather than a uniform cycle. Notably, the 0% late payment rate indicates that even extended payments are ultimately honored within agreed or expected contractual limits.
The distribution across three distinct payment bands — 52% under 30 days, 32% at 31-60 days, and 16% over 60 days — reveals moderate variability in payment timing, making cash flow forecasting somewhat unpredictable for suppliers. The 16% of payments exceeding 60 days represents a meaningful minority that could strain supplier liquidity if invoice values are high or if multiple payments cluster in this band simultaneously. However, the complete absence of late payments reduces the risk of default or dispute, pointing to a reliable but inconsistently timed payer.
ZOGENIX INTERNATIONAL LIMITED presents a moderate payment risk profile: financially reliable with no late payments, but operationally inconsistent due to a 44-day average that exceeds standard net-30 terms. Suppliers should factor extended payment windows into their cash flow planning and consider negotiating clear payment terms of net-45 to align expectations with observed behavior. For higher-value contracts, requesting partial upfront payments or early payment incentives could help mitigate the impact of the 16% of invoices that extend beyond 60 days.
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 29 Jul 2025 | 44 | 52% | 32% | 16% | 0% |
| 01 Jul 2024 - 31 Dec 2024 | 31 Jan 2025 | 32 | 42% | 53% | 5% | 13% |
| 01 Jan 2024 - 30 Jun 2024 | 19 Jul 2024 | 32 | 43% | 53% | 5% | 13% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
UCB payment terms are 60 days for most vendors. Some vendors are paid on 30 days.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
90
Any disputes regarding payments are logged with our Account Payables Helpdesk. It will be raised with the payment team and cause and resolution will be investigated. if there is any escalation it will be referred to the local the local accounts payables team lead.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Zogenix International Limited is a private limited company operating within the pharmaceutical and biotechnology sector. The company forms part of the Zogenix group, which focuses on the development and commercialisation of specialist medicines and therapeutic treatments.
The company was incorporated on 13 December 2012 and is registered in England and Wales under company number 08330213. Its registered office is located at Windlesham Campus, Sunninghill Road, Windlesham, Surrey, GU20 6PP, situating the business within the South East of England.
As an international pharmaceutical entity operating in the UK market, Zogenix International Limited is engaged in activities typical of the life sciences industry, including the regulatory management, licensing, and distribution of medicinal products. Such organisations work within the framework of UK and European medicines regulation to bring specialist treatments to patients and healthcare providers.
The company maintains an active status on the Companies House register, reflecting its continued operational presence in the UK pharmaceutical landscape.